An update on stem cell transplantation in autoimmune rheumatologic disorders

Current Allergy and Asthma Reports

Volumn 12, Issue 6, 2012, Pages 530-540

  Mascarenhas, Sheryl ^a   Avalos, Belinda ^a   Ardoin, Stacy P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antiphospholipid syndrome; Autoimmune disease; Dermatomyositis; Hematopoietic stem cell transplant; Mesenchymal stem cell transplant; Pathophysiology; Polymyositis; Rheumatic disease; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

ABATACEPT; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE PAIN; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE INFERTILITY; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADISM; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION SYNDROME; MALE INFERTILITY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROSCOPIC POLYANGIITIS; MYOSITIS; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; VOMITING; WEGENER GRANULOMATOSIS;

ADULT; AUTOIMMUNE DISEASES; CHILD; CONNECTIVE TISSUE DISEASES; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 84870586430     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0298-8     Document Type: Article

References (93)

1. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S48-56.
2. Hönig M, Schulz A, Friedrich W. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Klin Padiatr. 2011;223(6):320-5.
3. Kiem HP, Jerome KR, Deeks SG, et al. Hematopoietic-stem-cellbased gene therapy for HIV disease. Cell Stem Cell. 2012;10 (2):137-47.
4. Chang JW, Hung SP, Wu HH, et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 2011;20(2):245-57.
5. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III Prosepective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared with Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Non-Hodgkin's Lymphoma. J Clin Oncol. 2009;27(28):4767-73.
6. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hematopoietic stem cell transplantation for severe refractory rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2301-9.
7. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71-4. (Pubitemid 27161245)
8. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284 (5411):143-7. (Pubitemid 29282067)
9. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-5. (Pubitemid 41671625)
10. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol. 2007;180:45-66.
11. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147-53. (Pubitemid 33741968)
12. Li HW, Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol. 2012;12(6):403-16.
13. Hénon PH, Sovalat H, Bourderont D. Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34+CD38-cells as predictive tool for hematopoietic engraftment. J Biol Regul Homeost Agents. 2001;15(1):62-7. (Pubitemid 32492730)
14. De Kleer I, Vasstert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic selftolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood. 2006;107 (4):1696-702. (Pubitemid 43242411)
15. Roord ST, de Jager W, Boon L, et al. Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood. 2008;111(10):5233-41.
16. Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70 (7):1285-8.
17. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025-32. (Pubitemid 47258180)
18. Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-27.
19. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509-25. (Pubitemid 47620502)
20. Szodoray P, Varoczy L, Papp G, et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol. 2012;41(2):110-5.
21. Steingrimsdottir H, Gruber A, Björkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85(8):832-8.
22. Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine. 2011;56(3):544-9.
23. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications in targeted therapy. J Rheumatol. 2012;39 (6):1120-4.
24. Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992;166(3):255-63.
25. Hu H, Stein-Streilein J. Hapten-immune pulmonary interstitial fibrosis (HIPIF) in mice requires both CD4+ and CD8+ T lymphocytes. J Leukoc Biol. 1993;54(5):414-22. (Pubitemid 23347840)
26. Rosa SB, Voltarelli JC, Chies JA, et al. The use of stem cells for the treatment of autoimmune diseases. Braz J Med Biol Res. 2007;40(12):1579-97.
27. Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol. 2011;23(6):519-29.
28. Oyama Y, BarrWG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant. 2007;40:549-55. (Pubitemid 47382125)
29. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002;100:1602-10. (Pubitemid 34925135)
30. Marjanovic Z, J. Snowden, M. Badoglio, et al.: Long-term outcomes of autologous haematopoietic stem cell transplantation in severe autoimmune diseases: an extended analysis of the EBMT database 1996-2011. Presented at the 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT). Geneva, Switzerland; April 1-4, 2012.
31. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haematopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. 2011;378 (9790):498-506.
32. Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell transplantation for systemic sclerosis - a singlecenter long term experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39(2):269-75.
33. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program. 2011;2011:280-4.
34. Scleroderma clinical trials: Astis Study. Available at http://www.sclero.org/medical/treatments/clinical-trials/current/astis/ato-z. html. Accessed June 2012.
35. Autologous stem cell transplantation international scleroderma (ASTIS) trial. Available at http://www.controlled-trials.com/ISRCTN54371254. Accessed June 2012.
36. van Laar JM, Farge D, Sont JK, et al.: The ASTIS Trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. [abstract LB0002]. Presented at EULAR. Berlin, Germany: June 6-9, 2012.
37. Musculoskeletal report: High-Dose Immune Suppression With or Without Stem Cell Transplants For Systemic Sclerosis. Available at http://www.mskreport.com/ articles.cfm?articleID01084. Accessed June 2012.
38. Illei GG, Cervera R, Burt RK, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70 (12):2071-4.
39. Song X, Lv HY, Sun LX, et al. Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients. Transplant Proc. 2011;43 (5):1924-7.
40. Mok CC, Ying, KY, Ng WL, et al.: Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide. Am J Med 2006, 119(4): 355. e25-e33.
41. Meng J, Wang J, Liang W, et al. Long-term remission after successful pregnancy in autologous peripheral blood stem cell transplanted system lupus erythematosus patients. Rheumatol Int. 2011;31(5):691-4.
42. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358 (9285):903-11. (Pubitemid 32900579)
43. Gonzalez-Rey E, Gonzalez MA, Varela N, et al. Human adiposederived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-8.
44. Wu CC, Wu TC, Liu FL, et al. TNF-α inhibitor reverse the effects of human umbilical cord-derived stem cells on experimental arthritis by increasing immunosuppression. Cell Immunol. 2012;273 (1):30-40.
45. Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004;31 (3):482-8. (Pubitemid 38337605)
46. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010;12(6):R210.
47. Park MJ, Park HS, Cho ML, et al. Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum. 2011;63(6):1668-80.
48. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012;11(3):203-6.
49. Mahil S, Marks D, McComrack M, et al. Dermatomyositis. Br J Hosp Med (Lond). 2012;73(2):C18-22.
50. Ra JC, Kang SK, Shin IS, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of cultureexpanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011;9:181.
51. Owaidah TM, Maghrabi K, Elkarouri MA, et al. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature. Bone Marrow Transplant. 2011;46(4):597-600.
52. Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol. 2008;14(6):359-60.
53. Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106 (8):2700-9. (Pubitemid 41510743)
54. Schilder AM. Wegener's Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483-7.
55. Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener's). Curr Treat Options Cardiovasc Med. 2012;14(2):164-76.
56. Daikeler T, Erley C, Mohren M, et al. Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener's Granulomatosis. Ann Rheum Dis. 2005;64 (4):646-7. (Pubitemid 40469102)
57. Kunitomi A, Ishikawa T, Tajima K, et al. Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia. Int J Hematol. 2006;83(3):262-5. (Pubitemid 44228004)
58. Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65 (4):508-14.
59. Daikeler T, Kötter I, Bocelli Tyndall C, et al. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann Rheum Dis. 2007;66(2):202-7. (Pubitemid 46226055)
60. Statkute L, Oyama Y, BarrWG, et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis. 2008;67(9):991-7. (Pubitemid 351956663)
61. Bornhäuser M, Aringer M, Theide C. Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. N Engl J Med. 2010;362(25):2431-2.
62. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004;63(10):1318-26. (Pubitemid 39273515)
63. Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular idiopathic arthritis: long-term followup of a prospective clinical trial. Arthritis Rheum. 2007;56 (7):2410-21. (Pubitemid 47173589)
64. Rabusin M, Andolina M, Maximova N, et al. Haematopoietic SCT in autoimmune diseases in children: rational and new perspectives. Bone Marrow Transplant. 2008;41 suppl 2:S96-9. (Pubitemid 351864717)
65. Chen J, Wang Y, Kunkel G, et al. Use of CD34+ autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus. Clin Rheumtol. 2005;24(5):464-8. 2 patients. (Pubitemid 43055035)
66. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168-76. (Pubitemid 38478643)
67. Krauss AC, Kamani NR. Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go. Bone Marrow Transplant. 2009;44:137-43.
68. Wulffraat NM, van Rooijen EM, Tewarie R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity. 2008;41(8):632-8.
69. Lawitschka A, Peters C, Seidel MG, et al. Long-term remission in pediatric Wegener granulomatosis following allo-SCT after reduced intensity conditioning. Bone Marrow Transplant. 2011;46 (3):462-3.
70. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63 (8):974-81. (Pubitemid 38961924)
71. Swart JF, Lindemans CA, van Royen A, et al. Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies. Curr Opin Rheumatol. 2012;24 (3):267-73.
72. Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther. 2008;10(5):217.
73. Blazer BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-58.
74. Pasquini MC,Wang Z, Horowitz MM, et al. report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transplant. 2010;2010:87-105.
75. Stamatoviæ D, Balint B, Tukiæ L, et al. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies. Vojnosanit Pregl. 2011;68(12):1026-32.
76. Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune disease, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004;34(10):877-81. (Pubitemid 39562137)
77. Burt RK, Shah SJ, Gheorghiade M, et al. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: "it is a matter of the heart". J Rheumatol. 2012;39 (2):206-9.
78. Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev. 2008;7:198-203.
79. Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for anautoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118:1693-8.
80. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141(1):1-9. (Pubitemid 40904634)
81. Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(5):359-65. (Pubitemid 38788497)
82. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997;19(7):643-5. (Pubitemid 27182485)
83. Scleroderma Cyclophosphamide or Transplantation Study (SCOT). Available at. https://www.fbo.gov/index? s0opportunity&mode0form&id0e3a055606954c423b4a4606326f96081& tab0core&-cview00. Accessed June 2012.
84. Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot study. Ann Rheum Dis. 2010;69(8):1423-9.
85. Sun L, Akiyama K, Zhang H, et al. Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells. 2009;27 (6):1421-32.
86. Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol Immunol. 2009;47(1):46-51.
87. Daikeler T, Hügle T, Farge D, et al. Allogenic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009;44(1):27-33.
88. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces longterm remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214-23.
89. Nevskaya T, Ananieva L, Bykovskaia S, et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford). 2009;48(1):61-4.
90. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467-75.
91. Carrion F, Nova E, Ruiz C, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19(3):317-22.
92. van Laar JM, Farge D, Tyndall A. Autologous stem cell transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis. 2005;64(10):1515. (Pubitemid 41623870)
93. Craciunescu OI, Steffey BA, Kelsey CR, et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplant trial. Int J Radiat Oncol Biol Phys. 2011;79(4):1248-55.